Increased levels of osteoprotegerin in hemodialysis patients.

摘要: Recently identified soluble circulating osteoprotegerin (OPG), a member of tumor necrosis factor receptor family, is the osteoclastogenesis inhibitory (OCIF). It acts as "decoy" for activator NF-kappaB ligand (RANKL) and antagonises RANKL/RANK activity. This way OPG exerts protective effect on bone, which also important in hyperparathyroidism. The studies measuring levels secondary hyperparathyroidism have shown contradictory results inconsistent conclusions. aim our work was to evaluate hemodialysis patients their correlation with intensity bone turnover, formation resorption. Serum levels, alkaline phosphatase activity (bALP) beta-CrossLaps (CTx) were measured control group (n = 20, age 30+/-6.7 years) two groups dialysis patients: first serum intact parathyroid hormone (iPTH) concentration below 200 pg/ml 28, 62.6+/-14.8 second iPTH above 16, 63.7+/-14.8 years). Compared controls, 6.4-fold higher patients. high PTH approximately 1.2-fold than low-PTH group. correlated weakly bALP (r 0.277, p 0.153), well CTx 0.018, 0.929) group, there an insignificant negative high-PTH -0.145, 0.593 r -0.219, 0.416, respectively). In conclusion, increase might protect against intensive loss patients, but this probably not mediated by increased formation; rather, it seems be consequence imbalance kinetics renal disease. precise role pathogenesis osteodystrophy remains unknown establishing requires further studies.